MSMichael Sabina

Michael Sabina

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Michael Sabina has a total of 51 co-authors. Here are the top co-authors by number of shared publications:

  • Amanda Rigdon

    Graduate Medical Education, Internal Medicine, Lakeland Regional Health Medical Center, United States

    4 shared publications
  • Anas Bizanti

    Lakeland Regional Health Medical Center, 1324 Lakeland Hills Blvd, Lakeland, FL 33805, USA

    4 shared publications
  • Aqeel Khanani

    Graduate Medical Education, Internal Medicine, Lakeland Regional Health Medical Center, United States

    3 shared publications
  • Joseph Massaro

    Graduate Medical Education, Internal Medicine, Lakeland Regional Health Medical Center, United States

    3 shared publications
  • Zein Barakat

    Department of Internal Medicine, Lakeland Regional Health Medical Center, Lakeland, USA

    3 shared publications
  • Andrew Lurie

    Lakeland Regional Health Medical Center, 1324 Lakeland Hills Blvd, Lakeland, FL 33805, USA

    2 shared publications

Latest Publications

  • Open Access

    Seven versus Fourteen Days of Antibiotics for Gram-Negative Bacteremia from a Urinary Tract Source: a Systematic Review and Meta-analysis

    by Graciela Luna, Andrea Rodriguez, Chidozie Igbonagwam, Zein Barakat, Daniela Carralero-Somoza, Zoya Khan, Garret Snyder, Mark Soliman, Imad Dibo, Michael Sabina

    Introduction The optimal duration of antibiotic therapy for Gram-negative bacteremia sourced from urinary tract infections (UTI) remains uncertain. We performed a systematic review and meta-analysis comparing short-course (approximately 7 days) versus prolonged-course (approximately 14 days) antibiotic therapy in this population. Methods We systematically searched PubMed, Embase, and ClinicalTrials.gov through 26 April 26 2025. Studies were included if they compared 7-day versus 14-day antibiotic therapy in Gram-negative bacteremia with ≥ 65% UTI source or performed a dedicated UTI subgroup analysis. Outcomes assessed included 30- and 90-day mortality and recurrence rates. Recurrence was defined as a repeat episode of Gram-negative bacteremia confirmed by a positive blood culture after completion of therapy, rather than recurrence of urinary tract infection alone. Risk ratios (RR) were pooled using a random-effects model. Noninferiority was assessed using a prespecified margin of RR 1.25, and superiority was assessed with a threshold of RR < 1.00. Results In total, six studies (three randomized trials, three observational cohorts) encompassing 4448 patients were included. There were no significant differences between short- and prolonged-course therapy for 30-day mortality (RR 0.97, 95% confident interval (CI) 0.64–1.47; p = 0.90), 30-day recurrence (RR 1.38, 95% CI 0.80–2.37; p = 0.24), 90-day mortality (RR 0.90, 95% CI 0.77–1.06; p = 0.20), or 90-day recurrence (RR 0.68, 95% CI 0.45–1.01; p = 0.06). Conclusions Our findings suggest that a 7-day course may be sufficient for most patients with UTI-sourced Gram-negative bacteremia.


  • Open Access

    Effect of Finerenone in Cardiovascular and Renal Outcomes: A Systematic Review and Meta-analysis

    by Juan Carlos Rivera-Martinez, Michael Sabina, Aqeel Khanani, Andrew Lurie, Amanda Rigdon, Waiel Abusnina, Luis Daniel Lugo Rosado, Anas Bizanti, Timir K. Paul

    Purpose Heart failure (HF) management is well-defined for reduced ejection fraction (HFrEF) but less so for mildly reduced (HFmrEF) or preserved ejection fraction (HFpEF). This meta-analysis evaluates the impact of Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, on cardiovascular and renal outcomes in these patient populations. Methods A systematic search in PubMed and Embase identified randomized controlled trials (RCTs) on Finerenone’s cardiovascular and renal effects. Three RCTs were included—FIDELIO-DKD, FIGARO-DKD, and FINEARTS-HF—encompassing 19,027 participants. Primary outcomes included cardiovascular death, HF hospitalization, and renal failure. Secondary outcomes focused on safety and adverse events like acute kidney injury and hyperkalemia. Meta-analyses were performed using hazard ratios (HR), confidence intervals (CI), and Relative Risk (RR). Results Finerenone was associated with a 20% reduction in HF hospitalization risk (HR 0.80, 95% CI: 0.72–0.90) and a 14% reduction in all-cause mortality (RR 0.86, 95% CI: 0.77–0.97). Finerenone did not significantly reduce cardiovascular death (HR 0.91, 95% CI: 0.82–1.01, p = 0.06). Renal failure rates were similar between Finerenone and placebo (RR 1.05, 95% CI: 0.65–1.68). Hyperkalemia incidence was significantly higher with Finerenone, with a RR of 2.31 (95% CI: 1.98–2.69). Conclusion This meta-analysis shows that Finerenone significantly reduces HF hospitalizations and all-cause mortality in patients with chronic kidney disease and heart failure. Further studies are needed to clarify its effects on cardiovascular death and renal failure.


  • Open Access

    Beta-Blockers in Patients with Myocardial Infarction and Preserved Left Ventricular Ejection: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

    by Michael Sabina, Shrinand Shah, Mason Grimm, Jean Carlo Daher, Paola Campillo, Mohammed Baraa Boozo, Ahmad Al-Abdouh, Waiel Abusnina, Fabrizio D’ Ascenzo, Anas Bizanti

    Background: The benefit of beta-blockers (BBs) for myocardial infarction (MI) patients with a preserved left ventricular ejection fraction (LVEF) is uncertain. While beneficial for a reduced LVEF, their efficacy with a preserved LVEF, especially with modern revascularization, is unclear. Methods: A PRISMA-guided systematic review and meta-analysis utilized PubMed and EMBASE. Three randomized controlled trials comparing outcomes in MI patients with a preserved LVEF treated with BBs versus no treatment were included. The primary outcome was composite all-cause mortality and MI; secondary outcomes were all-cause mortality, cardiovascular mortality, MI, and stroke. Results: Three studies, including a total of 9512 participants, were analyzed. Beta-blockers did not demonstrate a statistically significant benefit in reducing the composite endpoint of all-cause mortality and myocardial infarction (RR 0.97, 95% CI: 0.84–1.12, p = 0.671, I2 = 0%). Similarly, no significant effect was observed for secondary outcomes: all-cause mortality (RR 0.96, 95% CI: 0.79–1.17, p = 0.708), cardiovascular mortality (RR 1.22, 95% CI: 0.87–1.72, p = 0.247), myocardial infarction (RR 0.97, 95% CI: 0.78–1.19, p = 0.759), and stroke (RR 0.96, 95% CI: 0.66–1.38, p = 0.819). Conclusions: In patients with myocardial infarction and a preserved LVEF, beta-blockers did not significantly reduce mortality, recurrent myocardial infarction, or stroke, suggesting a limited benefit in this population under contemporary management protocols.


  • Open Access

    Finerenone: A Third-Generation MRA and Its Impact on Cardiovascular Health—Insights from Randomized Controlled Trials

    by Michael Sabina, Jennifer Trube, Shrinand Shah, Andrew Lurie, Mason Grimm, Anas Bizanti

    Introduction: Finerenone, a third-generation non-steroidal mineralocorticoid receptor antagonist (MRA), offers a targeted approach to managing cardiovascular outcomes, particularly in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). Unlike traditional MRAs such as spironolactone and eplerenone, which can cause off-target hormonal side effects and hyperkalemia, Finerenone selectively binds to mineralocorticoid receptors, reducing these risks. Recent randomized controlled trials have demonstrated Finerenone’s potential to improve cardiovascular outcomes, making it a promising alternative in the management of heart failure and other cardiovascular conditions associated with CKD and T2D. Methods: We conducted a scoping review using PRISMA guidelines. A search for “Finerenone” in the PubMed, Embase, and Cochrane Library databases included randomized controlled trials (RCTs), post hoc analyses, and relevant meta-analyses on cardiovascular outcomes. Data were synthesized narratively, assessing study quality through strengths and limitations. Discussion: Finerenone has shown significant benefits and a superior safety profile compared with traditional MRAs like spironolactone and eplerenone in managing CKD, T2D, and heart failure. It effectively reduces cardiovascular and renal events while minimizing risks such as hyperkalemia and hormonal side effects associated with steroidal MRAs. Future studies, including the REDEFINE-HF, FINALITY-HF, and CONFIRMATION-HF trials, will further explore Finerenone’s potential across diverse heart failure phenotypes, including its role in heart failure with mildly reduced and preserved ejection fractions, potentially establishing it as a cornerstone therapy in heart failure management. Conclusions: Finerenone represents a significant advancement in MRA therapy, offering enhanced safety and efficacy in managing cardiovascular outcomes in CKD and T2D patients. The current evidence supports its use as a promising alternative to traditional MRAs, particularly in patients intolerant to steroidal MRAs. Further trials are needed to fully establish its potential across diverse patient populations, including those with varying heart failure phenotypes.


  • Open Access

    International incidence of melanoma in heart transplant recipients: a meta-analysis

    by Paola Campillo, Alice Kesler, Carlos J. Ramírez, Jean Carlo Daher, Mason Grimm, Michael Sabina, Anas Bizanti

    The incidence of heart transplants in the USA has increased by 85.8% since 2011, resulting in a growing population of recipients requiring long-term immunosuppressive therapy. While essential for preventing organ rejection, this therapy significantly increases melanoma risk. This meta-analysis investigates the incidence and risk factors of melanoma in heart transplant recipients. A systematic review and meta-analysis were conducted following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, including observational studies reporting melanoma incidence in heart transplant recipients. Relative risk (RR) was synthesized from standardized incidence ratios, hazard ratios, incidence rate ratios, and standardized mortality ratios. The meta-analysis incorporated 10 studies, including 22 415 heart transplant recipients. The pooled RR was 2.21 (95% confidence interval: 1.32–3.71; P = 0.003), indicating a significantly elevated melanoma risk. This study highlights the critical need for preventive dermatological strategies in heart transplant recipients and calls for further research into the impact of different immunosuppressive regimens on melanoma risk. Despite limitations, these findings offer valuable insights for optimizing long-term patient care.


  • Open Access

    Management of PFO in paradoxical embolic stroke with hemorrhagic conversion: a case report

    by Michael Sabina, Aqeel Khanani, Joshua Tsai, Amanda Rigdon, Joseph Massaro

    A paradoxical embolism is defined as a venous thrombus that crosses through a heart defect, into the systemic circulation, usually through a patent foramen ovale. Treatment varies between closure of patent foramen ovale vs. medical management based on a variety of individual risk factors and the cardiac defect's characteristics. We describe a case of paradoxical stroke complicated by hemorrhagic conversion, ultimately requiring an IVC filter.

  • Open Access

    PCI vs. CABG in left main with multi-vessel coronary artery disease and diabetes: Case report

    by Michael Sabina, Aqeel Khanani, Amanda Rigdon, Joshua Tsai, Joseph Massaro

    This case challenges the conventional preference for coronary artery bypass grafting (CABG) over percutaneous coronary intervention (PCI) in patients with diabetes, left main coronary artery disease (LMCAD) and multivessel disease. Current guidelines generally recommend CABG, especially in the context of LMCAD. However, our case involves a male patient with diabetes with LMCAD and extensive multivessel disease who was successfully treated with PCI, demonstrating a favorable outcome. Despite the high-risk profile, including a SYNTAX score of 28, the PCI approach was selected. This decision was supported by evidence suggesting comparable outcomes between PCI and CABG in similar patients. Our case highlights the potential of PCI as not just a viable, but potentially superior alternative in specific high-risk patients with diabetes, contrary to the prevailing belief in favor of CABG for all patients with left main involvement.

  • Open Access

    Diagnostic and Therapeutic Ambiguities in Diabetic Ketoacidosis With Overlapping Acute Pancreatitis and Hypertriglyceridemia

    by Michael Sabina, Amanda Rigdon, Joshua Tsai

    This case report discusses the diagnostic challenges and management complexities in a patient presenting with symptoms of diabetic ketoacidosis (DKA) and severe pancreatitis, complicated by concurrent hypertriglyceridemia (HTG) and superior mesenteric vein (SMV) thrombosis. The presence of DKA in acute pancreatitis suggests very severe impact on the pancreas. Hence, it calls for screening with CT imaging for complications like hemorrhagic pancreatitis, necrotizing pancreatitis, or even thrombus. Despite typical reliance on clinical presentation and serum lipase for diagnosing pancreatitis, this case emphasizes the necessity of contrast-enhanced CT imaging in ambiguous cases to identify critical complications like thrombosis and necrotizing pancreatitis. Furthermore, the patient's management involved insulin therapy for DKA and HTG-induced acute pancreatitis, deferring plasmapheresis and anticoagulation due to the risk of hemorrhagic transformation in pancreatitis. This approach highlights the need for individualized treatment strategies, especially in complex presentations with overlapping pathologies. The case also explores the potential for insulin as a first-line treatment in HTG-induced pancreatitis over plasmapheresis, contributing to evolving guidelines.